Clinical Report: Clinical Trial Update January 2026
Overview
This report summarizes ongoing clinical trials targeting age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and uveitis. Notable studies include evaluations of various investigational therapies, including ONL1204 and SAR446597, highlighting advancements in treatment options.
Background
The management of AMD, DME, RVO, and uveitis remains a critical focus in ophthalmology due to their significant impact on vision and quality of life. Recent guidelines emphasize the importance of timely intervention and the use of anti-VEGF therapies as first-line treatments. Ongoing clinical trials are essential for evaluating new therapies and improving patient outcomes.
Data Highlights
No numerical data available in the source material.
Key Findings
- Evaluation of OLX10212 in neovascular AMD has been completed.
- ONL1204 is being studied for efficacy and safety in geographic atrophy associated with AMD.
- A phase 2 study is assessing dapagliflozin for safety and efficacy in geographic atrophy secondary to AMD.
- SAR446597 is under investigation for its safety and efficacy in geographic atrophy secondary to AMD.
- ABBV-6628 is being evaluated for pharmacokinetics and exploratory efficacy in geographic atrophy secondary to AMD.
Clinical Implications
Healthcare professionals should stay informed about the latest clinical trials and emerging therapies for AMD, DME, RVO, and uveitis. Participation in clinical trials may provide patients access to novel treatments and contribute to the advancement of care in these conditions.
Conclusion
The ongoing clinical trials reported in January 2026 reflect a commitment to advancing treatment options for retinal diseases. Continued research is vital for improving patient outcomes and refining therapeutic strategies.
Related Resources & Content
- Retinal Physician, Clinical Trial Update January/February 2025
- Retinal Physician, Clinical Trial Update April 2025
- Retinal Physician, Clinical Trial Update April 2022 Recommendations
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- retinal physician — Clinical Trial Update January/February 2025
- Diabetic Retinopathy Preferred Practice Pattern® - PubMed
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - ScienceDirect
- HIGHLIGHTS OF PRESCRIBING INFORMATION
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.